Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of Trodelvy versus physician's choice chemotherapy in previously treated endometrial cancer
jRCT2051240165Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan, doxorubicin and paclitaxel in endometrial cancer (EC) and endometrial carcinosarcoma (2 arms), sponsored by Gilead Sciences. Primary endpoints: Progression-Free Survival (PFS) as assessed by Blinded Independent Central Review and Overall Survival (OS). Started Nov 2024; status: active, not recruiting.
02
Drugs
sacituzumab govitecandoxorubicinpaclitaxel
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on jRCT2051240165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240165.